Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir

• DOI: 10.3350/cmh.2015.21.1.24
• Publication Date: 2015-03-29T00:14:37Z
• Authors: Han Na Choi; Jeong Eun Song; Hyeon Chul Lee; Hyeong Ho Jo; Chang Hyeong Lee; Byung Seok Kim
• Keywords: Entecavir; HBeAg; Hepatitis B; Combination therapy

Background/Aims The optimal management of patients exhibiting a partial virologic response (PVR) to entecavir (ETV) has not been determined. aim this study was determine the long-term efficacy prolonged ETV monotherapy in treatment-naïve chronic hepatitis B (CHB) PVR therapy. Methods This included 364 CHB treated with for ≥48 weeks and who received continuous ≥96 weeks. defined as decrease serum virus (HBV) DNA more than 2 log10 IU/mL from baseline but detectable HBV by real-time PCR assay at week 48. Results Fifty-two (14.3%) showed PVR. Among them, 41 (median duration 144 weeks, range 96-312 weeks), 40 these (95%) achieved (VR, <20 IU/mL) during 78 60-288 weeks). cumulative probabilities VR 96, 144, 192 treatment initiation were 78.0%, 92.7%, 95.1%, respectively. rate 97.2% (35/36) HBeAg-positive 100% (5/5) HBeAg-negative patients. In multivariate analysis, HBeAg positivity (odds ratio [OR], 9.231; 95% confidence interval [CI], 1.03-82.91; P=0.047) high level (OR, 0.170; CI, 0.08-0.37; P=0.000) independently associated delayed response. No patient developed genotypic resistance follow-up. Conclusions Long-term is effective achieving ETV. Keywords: Chronic B; Entecavir; Partial